View Financial HealthRoche Holding 配当と自社株買い配当金 基準チェック /56Roche Holding配当を支払う会社であり、現在の利回りは3.1%で、収益によって十分にカバーされています。主要情報3.1%配当利回り0.4%バイバック利回り総株主利回り3.5%将来の配当利回り3.3%配当成長2.1%次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向61%最近の配当と自社株買いの更新Roche Holding Proposes DividendJan 29+ 1 more updateRoche Holding AG Approves DividendMar 26すべての更新を表示Recent updatesRoche Showcases Ophthalmology Portfolio At Arvo 2026May 02+ 1 more updateRoche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus ErythematosusApr 21Roche Receives CE Mark for New Elecsys NfL Blood Test to Detect Neuroinflammation in Multiple SclerosisApr 13Roche Launches the Cobas MPX-E Assay, A New 4-In-1 Donor Screening TestMar 30Roche Launches the Cobas Eplex Respiratory Pathogen Panel 3Mar 24Roche Holding AG to Report Q1, 2026 Results on Apr 23, 2026Mar 19+ 2 more updatesRoche Diagnostics Expands Mass Spectrometry Menu With Steroid Assays Receiving CLIA Moderate Complexity DesignationMar 18+ 1 more updateRoche Holding Ag Elects Lubomira Rochet to the Board of DirectorsMar 11+ 1 more updateRoche Provides Update On Phase III Persevera Study In Er-Positive Advanced Breast CancerMar 10Roche Holding Ag Announces Positive Phase Ii Results for Petrelintide, an Amylin Analog Developed for People Living with Overweight and ObesityMar 06FDA Accepts New Drug Application for Roche’s Giredestrant in ESR1-Mutated, Er-Positive Advanced Breast CancerFeb 20Roche Announces the Appointment of Mark Dawson as New Head of Roche Pharma Research and Early Development and Member of the Enlarged Corporate Executive Committee, Effective 1 May 2026Feb 18+ 1 more updateRoche Announces Positive Phase III Results for Gazyva/Gazyvaro in Primary Embarked A Significant Milestone in This Auto Autoimmune DiseaseFeb 17Roche Holding Proposes DividendJan 29+ 1 more updateRoche Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living with ObesityJan 27Roche Holding AG to Report Fiscal Year 2025 Results on Jan 29, 2026Jan 05Roche Announces U.S. Launch of Next-Generation Cobas 6800/8800 Systems and Software, Enhancing Laboratory Efficiency and Testing CapabilitiesDec 17Roche Receives FDA Approval for First Diagnostic Tests to Identify HER2-Positive Metastatic Breast Cancer Patients Eligible for ENHERTUDec 16European Commission Approves Gazyva/Gazyvaro for Adults with Active Lupus NephritisDec 10+ 1 more updateRoche Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive LymphomasDec 09+ 1 more updateRoche Receives FDA Clearance with CLIA waiver and CE Mark for its First Point-Of-Care Test for Diagnosing Bordetella Infections, Including Whooping Cough (pertussis)Dec 04European Commission Approves Roche's Lunsumio Subcutaneous for Relapsed or Refractory Foothicular LymphomaNov 20Roche's Giredestrant Becomes the First Oral SerD to Show Superior Invasive Disease-Free Survival in Early Breast CancerNov 18Roche's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple SclerosisNov 10Roche to Present New Data from its Broad and Innovative Haematology Portfolio at ASH 2025Nov 04Roche Announces Positive Phase III Data for Roche’s Gazyva/Gazyvaro Show Significant Reduction in Disease Activity for Systemic Lupus ErythematosusNov 03Roche Holding AG (SWX:ROG) completed the acquisition of 89bio, Inc. (NasdaqGM:ETNB) in a tender offer transaction.Oct 30Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Children and Young Adults with Idiopathic Nephrotic SyndromeOct 28Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026Oct 23Cmedsir Announces the Positive Results of Its Empress Study, Conducted in Collaboration with Roche FarmaOct 21+ 1 more updateFDA Approves Genentech's Gazyva for the Treatment of Lupus NephritisOct 20Roche’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People with ER-Positive Advanced Breast CancerOct 19Roche Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular EdemaOct 18CHMP Recommends EU Approval of Roche's Gazyva/Gazyvaro for Lupus NephritisOct 17Roche Receives CE Mark for AI-Based Kidney Klin Risk Algorithm and Launches New Comprehensive Chronic Kidney Disease (CKD) Algorithm PanelOct 08Claudia Süssmuth Dyckerhoff Decides Not to Stand for Re-Election as a Member of the Roche Board of DirectorsOct 03+ 1 more updateRoche Announces Primary Results from the TSIX Study ProgramOct 02Roche Presents New Data for OCREVUS and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025Sep 24Roche S.A. Announces Positive Phase III Results Show Roche's Giredestrant Significantly Improved Pro progression-Free Survival in ER-Positive Advanced Breast CancerSep 22CHMP Recommends EU Approval of Roche's Subcutaneous Formulation of Lunsumio for People with Relapsed or Refractory Follicular LymphomaSep 20Roche Achieves First CLIA 'Moderate Complexity' categorization for Ionify®? 25-Hydroxy Vitamin D Total TestSep 18+ 1 more updateRoche Announces New Data Reinforcing Efficacy and Safety of Vabysmo in Treating nAMDSep 05Roche's First Respiratory Test Powered by TAGS Technology Receives FDA Clearance for SARS-CoV-2, Influenza A, Influenza B and RSVAug 05Roche Announces its New Innovations In-Booth at Association for Diagnostics & Laboratory Medicine Scientific Meeting and Clinical Lab ExpoJul 24Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJun 18Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell LymphomaMay 21Roche Holding AG, Annual General Meeting, Sep 10, 2025May 19Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's At Ad/Pd 2025Apr 04Roche Holding AG Provides Update on Phase III Ocrevus High Dose Study in People with Relapsing Multiple SclerosisApr 02Roche Holding AG Approves DividendMar 26Roche Announces Management ChangesMar 20Roche Holding AG to Present New Data At the Muscular Dystrophy Association Conference from 16-19 March, 2025Mar 17Roche Announces CHMP Recommends EU Approval of Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell LymphomaMar 01Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion TechnologyFeb 21Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) ClearanceFeb 15Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).Feb 07Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related BlindnessFeb 05Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTUFeb 01Roche Holding AG Reports Earnings Guidance for the Year 2025Jan 30+ 1 more updateRoche Announces Executive and Committee ChangesJan 29Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast CancerJan 28+ 1 more updateRoche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of CareJan 22Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital PathologyJan 09Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025Jan 02Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal ConditionsDec 13New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with LymphomaDec 10Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive LymphomaDec 09U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell LymphomaDec 05Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERANov 25Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024Nov 05Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s DiseaseNov 02Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical TrialsOct 19+ 1 more updateRoche Presents Positive Two-Year Data from the Ongoing Rainbowfish StudyOct 14FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA MutationOct 11Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).Oct 02Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple SclerosisSep 14FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer ImmunotherapySep 13Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple SclerosisSep 04Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNHAug 27European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)Jul 30Roche Holding AG Raises Earnings Guidance for the Year 2024Jul 25BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by RocheJul 23New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye ConditionsJul 18+ 1 more updateHealth Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung CancerJul 17決済の安定と成長配当データの取得安定した配当: RHHB.Fの1株当たり配当金は過去10年間安定しています。増加する配当: RHHB.Fの配当金は過去10年間にわたって増加しています。配当利回り対市場Roche Holding 配当利回り対市場RHHB.F 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (RHHB.F)3.1%市場下位25% (US)1.4%市場トップ25% (US)4.3%業界平均 (Pharmaceuticals)2.2%アナリスト予想 (RHHB.F) (最長3年)3.3%注目すべき配当: RHHB.Fの配当金 ( 3.1% ) はUS市場の配当金支払者の下位 25% ( 1.42% ) よりも高くなっています。高配当: RHHB.Fの配当金 ( 3.1% ) はUS市場の配当金支払者の上位 25% ( 4.3% ) と比較すると低いです。株主への利益配当収益カバレッジ: RHHB.Fの配当金は、合理的な 配当性向 ( 60.6% ) により、利益によって賄われています。株主配当金キャッシュフローカバレッジ: RHHB.Fは合理的な 現金配当性向 ( 59.6% ) を備えているため、配当金の支払いはキャッシュフローによって賄われます。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/04 21:12終値2026/05/04 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Roche Holding AG 17 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。47 アナリスト機関John StaszakArgus Research CompanyGerhard SchwarzBaader Helvea Equity ResearchMark PurcellBarclays44 その他のアナリストを表示
Roche Announces FDA Acceptance of Application for Gazyva Gazyvaro for Treatment of Systemic Lupus ErythematosusApr 21
Roche Receives CE Mark for New Elecsys NfL Blood Test to Detect Neuroinflammation in Multiple SclerosisApr 13
Roche Diagnostics Expands Mass Spectrometry Menu With Steroid Assays Receiving CLIA Moderate Complexity DesignationMar 18+ 1 more update
Roche Holding Ag Announces Positive Phase Ii Results for Petrelintide, an Amylin Analog Developed for People Living with Overweight and ObesityMar 06
FDA Accepts New Drug Application for Roche’s Giredestrant in ESR1-Mutated, Er-Positive Advanced Breast CancerFeb 20
Roche Announces the Appointment of Mark Dawson as New Head of Roche Pharma Research and Early Development and Member of the Enlarged Corporate Executive Committee, Effective 1 May 2026Feb 18+ 1 more update
Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Primary Embarked A Significant Milestone in This Auto Autoimmune DiseaseFeb 17
Roche Announces Positive Phase II Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People Living with ObesityJan 27
Roche Announces U.S. Launch of Next-Generation Cobas 6800/8800 Systems and Software, Enhancing Laboratory Efficiency and Testing CapabilitiesDec 17
Roche Receives FDA Approval for First Diagnostic Tests to Identify HER2-Positive Metastatic Breast Cancer Patients Eligible for ENHERTUDec 16
European Commission Approves Gazyva/Gazyvaro for Adults with Active Lupus NephritisDec 10+ 1 more update
Roche Presents Lunsumio Data Showing Potential Across Earlier Treatment Lines in Indolent and Aggressive LymphomasDec 09+ 1 more update
Roche Receives FDA Clearance with CLIA waiver and CE Mark for its First Point-Of-Care Test for Diagnosing Bordetella Infections, Including Whooping Cough (pertussis)Dec 04
European Commission Approves Roche's Lunsumio Subcutaneous for Relapsed or Refractory Foothicular LymphomaNov 20
Roche's Giredestrant Becomes the First Oral SerD to Show Superior Invasive Disease-Free Survival in Early Breast CancerNov 18
Roche's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple SclerosisNov 10
Roche Announces Positive Phase III Data for Roche’s Gazyva/Gazyvaro Show Significant Reduction in Disease Activity for Systemic Lupus ErythematosusNov 03
Roche Holding AG (SWX:ROG) completed the acquisition of 89bio, Inc. (NasdaqGM:ETNB) in a tender offer transaction.Oct 30
Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Children and Young Adults with Idiopathic Nephrotic SyndromeOct 28
Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026Oct 23
Cmedsir Announces the Positive Results of Its Empress Study, Conducted in Collaboration with Roche FarmaOct 21+ 1 more update
Roche’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People with ER-Positive Advanced Breast CancerOct 19
Roche Receives CE Mark for AI-Based Kidney Klin Risk Algorithm and Launches New Comprehensive Chronic Kidney Disease (CKD) Algorithm PanelOct 08
Claudia Süssmuth Dyckerhoff Decides Not to Stand for Re-Election as a Member of the Roche Board of DirectorsOct 03+ 1 more update
Roche Presents New Data for OCREVUS and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025Sep 24
Roche S.A. Announces Positive Phase III Results Show Roche's Giredestrant Significantly Improved Pro progression-Free Survival in ER-Positive Advanced Breast CancerSep 22
CHMP Recommends EU Approval of Roche's Subcutaneous Formulation of Lunsumio for People with Relapsed or Refractory Follicular LymphomaSep 20
Roche Achieves First CLIA 'Moderate Complexity' categorization for Ionify®? 25-Hydroxy Vitamin D Total TestSep 18+ 1 more update
Roche's First Respiratory Test Powered by TAGS Technology Receives FDA Clearance for SARS-CoV-2, Influenza A, Influenza B and RSVAug 05
Roche Announces its New Innovations In-Booth at Association for Diagnostics & Laboratory Medicine Scientific Meeting and Clinical Lab ExpoJul 24
Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's DiseaseJun 18
Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell LymphomaMay 21
Roche Holding AG Provides Update on Phase III Ocrevus High Dose Study in People with Relapsing Multiple SclerosisApr 02
Roche Holding AG to Present New Data At the Muscular Dystrophy Association Conference from 16-19 March, 2025Mar 17
Roche Announces CHMP Recommends EU Approval of Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell LymphomaMar 01
Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion TechnologyFeb 21
Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related BlindnessFeb 05
Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTUFeb 01
Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast CancerJan 28+ 1 more update
Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of CareJan 22
Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal ConditionsDec 13
New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with LymphomaDec 10
Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive LymphomaDec 09
U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell LymphomaDec 05
Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERANov 25
Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024Nov 05
Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s DiseaseNov 02
Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical TrialsOct 19+ 1 more update
FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA MutationOct 11
Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).Oct 02
Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple SclerosisSep 14
FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer ImmunotherapySep 13
Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple SclerosisSep 04
Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNHAug 27
BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by RocheJul 23
New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye ConditionsJul 18+ 1 more update
Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung CancerJul 17